Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of ocrelizumab versus placebo and Avonex in relapsing-remitting multiple sclerosis
2007-006338-32Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (4 arms), sponsored by Roche. Primary endpoint: Total number of gadolinium-enhancing T1 brain MRI lesions. Started Feb 2008; status: completed.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2007-006338-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006338-32.